The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Personalized Medicine Biomarkers Market During 2026–2030?
The personalized medicine biomarkers market has experienced rapid expansion in recent years. It is projected to increase from $26.73 billion in 2025 to $31.34 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.3%. The historical development of this market is primarily due to advances in genomic research, a rise in cancer incidence, the proliferation of targeted therapies, enhanced utilization of molecular diagnostics, and strong regulatory support for precision medicine.
The personalized medicine biomarkers market size is set to experience swift expansion in the coming years. This market is projected to reach $58.8 billion by 2030, showing a compound annual growth rate (CAGR) of 17.0%. The anticipated growth over the forecast period stems from the broader implementation of personalized therapeutics, a rising need for early disease detection, advancements in pharmacogenomics, increased investment in biomarker discovery, and wider acceptance across non-oncology indications. Prominent trends for this period include the growing embrace of precision treatment strategies, expanded application of biomarkers in oncology care, increasing incorporation of companion diagnostics, the proliferation of predictive and prognostic biomarkers, and a heightened emphasis on monitoring treatment response.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp
What Underlying Factors Are Accelerating The Growth Of The Personalized Medicine Biomarkers Market?
The increasing occurrence of chronic diseases is anticipated to boost the expansion of the personalized medicine biomarkers market in the future. These enduring health conditions advance gradually, lasting for at least a year, and necessitate continuous medical care or restrict daily life. This rise in chronic disease prevalence stems from poor lifestyle choices, inadequate nutrition, insufficient physical activity, and elevated stress levels. Personalized medicine biomarkers are instrumental in customizing treatments for chronic conditions by pinpointing effective therapies, forecasting disease progression, and reducing negative side effects, all based on a person’s unique genetic and molecular makeup. A relevant illustration comes from February 2024, when the World Health Organization (WHO), a Switzerland-based health authority, projected that by 2050, new cancer cases would exceed 35 million, marking a 77% surge from the approximate 20 million cases in 2022. Consequently, the expanding presence of chronic diseases is fueling the growth of the personalized medicine biomarkers market.
How Are The Various Segments Of The Personalized Medicine Biomarkers Market Categorized?
The personalized medicine biomarkers market covered in this report is segmented –
1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types
2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications
3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring
4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users
Subsegments:
1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers
2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers
3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers
4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers
What Trends Are Affecting The Expansion Of The Personalized Medicine Biomarkers Market?
Leading companies in the personalized medicine biomarkers market are concentrating on acquiring regulatory authorizations, including companion diagnostic approval, to bolster precision oncology by swiftly connecting patients with targeted treatments. Companion diagnostic approval signifies the official permission granted by a health authority, such as the FDA, for a diagnostic test specifically designed to identify patients most likely to benefit from a particular therapeutic product or those at higher risk of adverse reactions. For example, in August 2024, Illumina, Inc., a US-based biotechnology company, obtained Food and Drug Administration (FDA) approval for its cancer biomarker test alongside two companion diagnostics. This test employs next-generation sequencing (NGS) technology to detect genetic mutations in cancer cells, empowering clinicians to select the most appropriate treatments based on individual biomarkers. This regulatory clearance signifies a substantial leap forward in precision oncology, aiming to enhance the swiftness and precision of treatment selection for cancer patients, ultimately improving personalized care.
Which Major Firms Influence Developments In The Personalized Medicine Biomarkers Market?
Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.
Read the full personalized medicine biomarkers market report here:
Which Region Is Projected To Dominate The Personalized Medicine Biomarkers Market During The Forecast Period?
North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Personalized Medicine Biomarkers Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23471&type=smp
Browse Through More Reports Similar to the Global Personalized Medicine Biomarkers Market 2026, By The Business Research Company
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Clinical Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Personalized Medicine Market Report 2026
https://www.thebusinessresearchcompany.com/report/personalized-medicine-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model